Comparative Pharmacokinetics and Bioequivalence Assessment of Metformin/Pioglitazone Tablet in Fasting and Fed Conditions: A Randomized Study in Healthy Chinese Subjects
Clinical Pharmacology in Drug Development · 2026-05 · 15 (5)
DOI: 10.1002/cpdd.70063 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 29.04.2026. Verfasst von Hongcheng Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Xiangya School of Pharmaceutical Science, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Fasting, Hypoglycemic Agents, Metformin, Pioglitazone. Die Arbeit nennt 18 Literaturangaben. Gefördert von: Hunan Science and Technology Youth Talent Support Program, science and technology innovation Program of Hunan Province.
Abstract (Originalsprache)
Metformin/pioglitazone tablets are a fixed‐dose combination of metformin hydrochloride and pioglitazone. In healthy Chinese subjects, this study evaluated the pharmacokinetics and bioequivalence of metformin/pioglitazone (500/15 mg) tablets. We conducted a single‐center, open‐label, randomized, two‐way crossover study in which subjects were randomized in a 1:1 ratio to either the test formulation or the reference formulation, separated by a 10‐day washout period. Blood samples collected at pre‐arranged intervals before and after dosing were analyzed using validated liquid chromatography‐tandem mass spectrometry techniques to determine metformin and pioglitazone plasma concentrations. Finally, subjects completed fasting and fed studies, respectively. In both studies, the 90% confidence intervals for the geometric mean ratios (test/reference) of C max , AUC 0–t , and AUC 0–∞ were within acceptable bioequivalence limits (0.80–1.25), and no serious adverse events were observed. The study demonstrated that the tested and reference formulations of metformin/pioglitazone tablets are bioequivalent and well tolerated under both fasting and fed conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Xiangya School of Pharmaceutical Science, Central South University, Changsha, China.
- Shouguang Fukang Pharmaceutical Co., Ltd., Shouguang, China.
- Weifang Hospital of Traditional Chinese Medicine, Shandong Second Medical University, Weifang, China.
- Changsha Duxact Biotech Co., Ltd., Changsha, China.
- Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha, China.
- Changsha Phamark Data Technology Co., Ltd., Changsha, China.
Förderung
- Hunan Science and Technology Youth Talent Support Program
- science and technology innovation Program of Hunan Province
Zitieren
APA
Li, H., Li, M., Liu, B., Wei, Z., Chen, L., Li, C., Fang, Q., Wang, X., Zhou, L., Ouyang, D., & Li, X. (2026). Comparative Pharmacokinetics and Bioequivalence Assessment of Metformin/Pioglitazone Tablet in Fasting and Fed Conditions: A Randomized Study in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development, 15(5). https://doi.org/10.1002/cpdd.70063
Vancouver
Li H, Li M, Liu B, Wei Z, Chen L, Li C, et al. Comparative Pharmacokinetics and Bioequivalence Assessment of Metformin/Pioglitazone Tablet in Fasting and Fed Conditions: A Randomized Study in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2026;15(5). doi:10.1002/cpdd.70063
BibTeX
@article{Li2026,
author = {Li, Hongcheng and Li, Mengke and Liu, Bin and Wei, Zijie and Chen, Lulu and Li, Chao and Fang, Qing and Wang, Xintong and Zhou, Ling and Ouyang, Dongsheng and Li, Xiaohui},
title = {Comparative Pharmacokinetics and Bioequivalence Assessment of Metformin/Pioglitazone Tablet in Fasting and Fed Conditions: A Randomized Study in Healthy Chinese Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {5},
doi = {10.1002/cpdd.70063}
}
EUVIMED